Lamark Biotech

Lamark Biotech, founded in 2018 by Dr. Vaibhav Bhatia, is a biopharmaceutical company focused on making essential medicines more accessible and affordable. Dr. Bhatia, a biochemist with a Ph.D. from the Indian Institute of Science, brings extensive experience in protein chemistry, gene transfer technologies, and business development to the firm. His background investigating molecular causes for diseases like retinal degeneration and breast cancer, combined with his work on protein folding and stability, directly informs the company's core mission. Headquartered in Ahmedabad, India, with R&D operations at the Venture Center, NCL Innovation Park in Pune, Lamark was established to address critical gaps in drug delivery for chronic and life-altering diseases.

The company's primary business involves developing formulations of biologics that are resistant to temperature fluctuations, thereby reducing the dependency on cold-chain logistics for storage and transportation. This is achieved through its proprietary ProteoStrong™ platform, which stabilizes fragile protein-based drugs like insulin, enzymes, and monoclonal antibodies without altering their molecular structure. By overcoming the need for constant refrigeration, Lamark aims to significantly cut costs and improve the availability of life-saving treatments in underserved regions, particularly in Asia and Africa where cold-chain infrastructure can be unreliable. The business model operates on a B2B framework, focusing on collaborating with pharmaceutical companies, Contract Development and Manufacturing Organizations (CDMOs), and global health agencies for API manufacturing, clinical trials, and marketing.

Lamark's flagship product is InsulinStrong, a thermostable, crystalline form of recombinant human insulin designed to be refrigeration-independent with a shelf life of two years at room temperature. This product directly targets the challenges of managing diabetes in developing nations. The company is initially focusing on India's ₹4,000 crore insulin market, with plans to expand into Southeast Asia and the UAE. Beyond insulin, Lamark is extending its platform technology to develop treatments for diabetic eye disease and cancer immunotherapy. The company has secured multiple rounds of funding, including a seed round of approximately $41,300 and a subsequent pre-Series A round of ₹6.5 crore in July 2025, to accelerate the development of its product pipeline, file international patents, and initiate early-stage clinical trials.

Keywords: thermostable biologics, drug delivery, protein stabilization, cold-chain independent, insulin formulation, ProteoStrong platform, biopharmaceutical, chronic diseases, Dr. Vaibhav Bhatia, InsulinStrong, monoclonal antibodies, gene therapies, cell therapies, affordable healthcare, healthcare accessibility, pharmaceutical partnerships, biologics formulation, diabetes care, cancer immunotherapy, drug discovery